We’re developing targeted therapies to lower LDL cholesterol for patients not adequately treated with current lipid-modifying therapies.

Learn More


Esperion is a late-stage pharmaceutical company focused on developing and commercializing non-statin, complementary, once-daily, oral, LDL-C lowering therapies for the treatment of patients with elevated hypercholesterolemia.

learn more


The Bempedoic Acid / Ezetimibe Combo Pill: Our Leading Complementary, Non-statin, Oral Therapy

This week we announced a major milestone: the U.S. Food and Drug Administration (FDA) confirmed the regulatory pathway to approval… more

Posted by mlowe@esperion.com

Setting the Record Straight: The Facts About Bempedoic Acid

We recently became aware of comments published containing misinterpretations or intentionally inaccurate statements regarding Esperion and bempedoic acid.  As the… more

Posted by mlowe@esperion.com

Cardiovascular Disease Awareness: Heart Healthy Initiatives Underway at Esperion

I am very excited to join my Esperion colleagues, their families and pets to participate in the Washtenaw County American… more

Posted by mlowe@esperion.com